Foresee's Board of Directors resolved to approve
the 2022Q2 consolidated financial report
Date of events
2022/08/08
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved: 2022/08/08
2.Date of the audit committee approved: 2022/08/05
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD): 273,645
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD): 268,109
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD): (89,625)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD): (73,652)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD): (100,498)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD): (100,498)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD): (0.85)
11.Total assets end of the period (thousand NTD): 1,572,693
12.Total liabilities end of the period
(thousand NTD): 325,923
13.Equity attributable to owners of parent end of the
period (thousand NTD): 1,246,770
14.Any other matters that need to be specified: None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Foresee Pharmaceuticals Co. Ltd. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 09:13:01 UTC.
Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.